Shenzhen Capital Group Co-leads $62m Round In Chinese Biopharmaceutical Firm Zelgen – China Money Network
Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences Co., Ltd., a Chinese biopharmaceutical company. Northern Light Venture Capital and China Youth Finance Network also participated in the round, according to a company announcement. Founded in 2009, Zelgen specialzes in the development, production and sale of innovative drugs. It also provides production and analysis services of cell strain, protein, antibody and peptide. One of … Shenzhen Capital Group Co-Leads $62M Round In Chinese Biopharmaceutical Firm Zelgen appeared first on China Money Network.